There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Omeros Corp (OMER), AnaptysBio Inc (ANAB) and Collegium Pharmaceutical (COLL) with bullish sentiments.
AnaptysBio Inc (ANAB)
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on AnaptysBio Inc, with a price target of $126. The company’s shares closed on Friday at $70.60.
Fein observed:
“Our 12-month price target of $126/share is based on an equally weighted composite of (a) $89/share, as a 35x multiple of taxed and diluted FY32 GAAP EPS of $27.28 discounted back to and (b) an NPV of $163/ share (discount rate 12.0%, growth rate 2.0%). The assumptions are in-line with the expected PE multiple and discount rate of an early development-stage biotechnology company.”
According to TipRanks.com, Fein is a 5-star analyst with an average return of 9.9% and a 48.3% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for AnaptysBio Inc with a $131.50 average price target, representing an 86.3% upside. In a report issued on February 22, Guggenheim also initiated coverage with a Buy rating on the stock with a $135 price target.
Collegium Pharmaceutical (COLL)
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Collegium Pharmaceutical, with a price target of $30. The company’s shares closed on Friday at $18.29.
According to TipRanks.com, Arce is a 4-star analyst with an average return of 10.1% and a 43.6% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Melinta Therapeutics Inc, and Conatus Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Collegium Pharmaceutical with a $32.67 average price target, representing a 78.6% upside. In a report issued on February 22, Cantor Fitzgerald also maintained a Buy rating on the stock with a $35 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
